Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-119664 · Präparat HOS-094989
Adults
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of
olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol,
glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia,
parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension,
anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4),
rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma
glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 74d1f63ed5b1572f8ebaf0ac1db6272b106b894a6b30df9f2e889bf9ab152f23 · Zeichen 1828–2515 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-119665 · Präparat HOS-094989
Tabulated list of adverse reactions
The following table lists the adverse reactions and laboratory investigations observed from spontaneous
reporting and in clinical trials. Within each frequency grouping, adverse reactions are presented in order
of decreasing seriousness. The frequency terms listed are defined as follows: Very common (≥ 1/10),
common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very
rare (< 1/10,000), not known (cannot be estimated from the data available).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 14e68e88928081dfc8196e23fc05bcfed36358f98871fd2fdbb63dc4f0db4a3f · Zeichen 2517–3037 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-119666 · Präparat HOS-094989
Very common Common Uncommon Rare Not known
Blood and the lymphatic system disorders
Eosinophilia Thrombocytopenia
Leukopenia10 11
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage a76fbc96c952a09f098be53316ee3453f049450cb34672fd92f44d13b51ee82c · Zeichen 3039–3312 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-119667 · Präparat HOS-094989
Neutropenia 10
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 611a81d9a0eb06b5dd9522baede85898c3ef6ece69b8e3ef8712903bdf9547f4 · Zeichen 3333–3348 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-119668 · Präparat HOS-094989
Immune system disorders
Hypersensitivity11
Metabolism and nutrition disorders
Weight gain1 Elevated Development or Hypothermia12
cholesterol exacerbation of
levels2,3 diabetes
Elevated glucose occasionally
levels 4
associated with
Elevated ketoacidosis or
triglyceride coma, including
levels2,5 some fatal cases
Glucosuria (see section 4.4)11
Increased appetite
Nervous system disorders
Somnolence Dizziness Seizures where in Neuroleptic
Akathisia6 most cases a malignant
Parkinsonism6 history of seizures syndrome (see
Dyskinesia6 or risk factors for section 4.4)12
seizures were Discontinuation
reported11 symptoms7, 12
Dystonia
(including
oculogyration)11
Tardive
dyskinesia11
Amnesia 9
Dysarthria
Stuttering11
Restless Legs
Syndrome 11
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 3a6d983fe95eb1d7716eb0957445932676b7afc6f742f7d2367f086edbc1e729 · Zeichen 3350–4980 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 10–11
HOS-119669 · Präparat HOS-094989
10
Cardiac disorders
Bradycardia Ventricular
QTc prolongation tachycardia/fibrill
(see section 4.4) ation, sudden
death (see section
4.4) 11
Vascular disorders
Orthostatic Thromboembolis
hypotension10 m (including
pulmonary
embolism and
deep vein
thrombosis) (see
section 4.4)
Respiratory, thoracic and mediastinal disorders
Epistaxis9
Gastrointestinal disorders
Mild, transient Abdominal Pancreatitis11
anticholinergic distension9
effects including Salivary
constipation and hypersecretion11
dry mouth
Hepatobiliary disorders
Transient, Hepatitis
asymptomatic (including
elevations of hepatocellular,
hepatic cholestatic or
aminotransferases mixed liver
(ALT, AST), injury)11
especially in early
treatment (see
section 4.4)
Skin and subcutaneous tissue disorders
Rash Photosensitivity Drug Reaction
reaction with Eosinophilia
Alopecia and Systemic
Symptoms
(DRESS)
Musculoskeletal and connective tissue disorders
Arthralgia9 Rhabdomyolysis11
Renal and urinary disorders
Urinary
incontinence
Urinary retention
Urinary
hesitation11
Pregnancy, puerperium and perinatal conditions
Drug withdrawal
syndrome
neonatal (see
section 4.6)
Reproductive system and breast disorders
Erectile Amenorrhea Priapism12
dysfunction in Breast
males enlargement
Decreased libido Galactorrhea in
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 0bc8fa377fde6dbdf6744598ba5717eb414d5b2d43d8141a29da72c352727c65 · Zeichen 5033–8356 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 11–12
HOS-119670 · Präparat HOS-094989
11
in males and females
females Gynaecomastia/
breast
enlargement in
males
General disorders and administration site conditions
Asthenia Injection site
Fatigue abscess
Oedema
Pyrexia10
Injection site pain
Investigations
Elevated plasma Increased alkaline Increased total
prolactin levels8 phosphatase10 bilirubin
High creatine
phosphokinase11
High Gamma
Glutamyltransfera
se 10
High uric acid 10
1
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight
was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %). Patients
gaining ≥ 7 %, ≥ 15 % and ≥ 25% of their baseline body weight with long-term exposure (at least 48
weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
2
Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were
greater in patients without evidence of lipid dysregulation at baseline.
3
Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - < 6.2 mmol/l) to high
(≥ 6.2 mmol/l) were very common.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 40e0987d79dc49b7c7354a9f2d3cad6f0aca52e404598b18275b5407ff500812 · Zeichen 8405–10151 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 12
HOS-119671 · Präparat HOS-094989
4
Observed for fasting normal levels at baseline (< 5.56 mmol/l) which increased to high (≥ 7 mmol/l).
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/l) to high (≥ 7 mmol/l) were
very common.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 6b23a5e68faa4c067e01f0d125acd1b64f0afe7589c5314967a24b05ed51f958 · Zeichen 10153–10372 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 12
HOS-119672 · Präparat HOS-094989
5
Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high
(≥ 2.26 mmol/l). Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l -
< 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage b54b622c81e22a161373abe97106bf01cc96553fda4b35c33bf4698dbbfeef6f · Zeichen 10374–10615 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 12
HOS-119673 · Präparat HOS-094989
6
In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was
numerically higher, but not statistically significantly different from placebo. Olanzapine-treated patients
had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses of
haloperidol. In the absence of detailed information on the pre-existing history of individual acute and
tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces
less tardive dyskinesia and/or other tardive extrapyramidal syndromes.
7
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported
when olanzapine is stopped abruptly.
8
In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal
range in approximately 30% of olanzapine treated patients with normal baseline prolactin value. In the
majority of these patients the elevations were generally mild, and remained below two times the upper
limit of normal range.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 222952a9cbdc718fb0b1735ca87efce21225ac9910f4e2e8209f764be4330006 · Zeichen 10617–11672 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 12–13
HOS-119674 · Präparat HOS-094989
12
9
Adverse event identified from clinical trials in the Olanzapine Integrated Database.
10
As assessed by measured values from clinical trials in the Olanzapine Integrated Database.
11
Adverse event identified from spontaneous post-marketing reporting with frequency determined
utilising the Olanzapine Integrated Database.
12
Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the
upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage bd05a1b51ccf24a46cfa901ea29d5b37c0963f40ca807846436c7aa164e3c58e · Zeichen 11725–12255 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119675 · Präparat HOS-094989
Long-term exposure (at least 48 weeks)
The proportion of patients who had adverse, clinically significant changes in weight gain, glucose,
total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12
months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage b1487d5eecae90ae5345661370e6e71220396dfab91841f22ba335857762911b · Zeichen 12257–12595 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119676 · Präparat HOS-094989
Additional information on special populations
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher
incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
Very common adverse reactions associated with the use of olanzapine in this patient group were
abnormal gait and falls. Pneumonia, increased body temperature, lethargy, erythema, visual
hallucinations and urinary incontinence were observed commonly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage caf80b416b523b694c1a379e99d956bb2c8c84cb118ff6d970d14cbc055b96ed · Zeichen 12597–13097 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119677 · Präparat HOS-094989
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s
disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly
and more frequently than with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 202a8070277d303fddbd3c40155da31eac3e1358e85f563e935c9eac19054e96 · Zeichen 13099–13340 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119678 · Präparat HOS-094989
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine
resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma
valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels (≥10%)
of tremor, dry mouth, increased appetite, and weight gain. Speech disorder was also reported
commonly. During treatment with olanzapine in combination with lithium or divalproex, an increase of
≥ 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar
disorder was associated with an increase of ≥7% from baseline body weight in 39.9% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage a7581e7778200ad62fd64b67b009648354fc1ba2858ac95dd5dacc7242d3b8e8 · Zeichen 13342–14138 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119679 · Präparat HOS-094989
Paediatric population
Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Although no clinical studies designed to compare adolescents to adults have been conducted, data from
the adolescent trials were compared to those of the adult trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage dcfb743d7157d90007b95c1d24e2d21fcd872b2cd5c9edc5728d4009080ea1d1 · Zeichen 14140–14427 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119680 · Präparat HOS-094989
The following table summarises the adverse reactions reported with a greater frequency in adolescent
patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term
clinical trials in adolescent patients. Clinically significant weight gain (≥ 7%) appears to occur more
frequently in the adolescent population compared to adults with comparable exposures. The magnitude
of weight gain and the proportion of adolescent patients who had clinically significant weight gain were
greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage ede1d8f6dd113e9f75dd4bb84e46346f52e2418df0799e6fb35ed6a46f26b0f0 · Zeichen 14429–15027 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119681 · Präparat HOS-094989
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The
frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 8e6b04a7739fa895b150d53221dfe84c5e76f050bfc5208cbcef9c21af1208af · Zeichen 15029–15229 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-119682 · Präparat HOS-094989
Metabolism and nutrition disorders
Very common: Weight gain13, elevated triglyceride levels14, increased appetite.
Common: Elevated cholesterol levels15
Nervous system disorders
Very common: Sedation (including: hypersomnia, lethargy, somnolence).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 4816da1efef762834dac9aea5cc18b8eff85bf4ac70587140f669331f6ae5de4 · Zeichen 15231–15478 im Abschnitt
Nebenwirkungen · Zypadhera
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13–14
HOS-119683 · Präparat HOS-094989
13
Gastrointestinal disorders
Common: Dry mouth
Hepatobiliary disorders
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4.4).
Investigations
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels16.
13
Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight
(kg) was very common (40.6 %), ≥ 15% of baseline body weight was common (7.1 %) and ≥ 25 % was
common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥
15 % and 29.1 % gained ≥ 25% of their baseline body weight.
14
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high
(≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l -
< 1.467 mmol/l) to high (≥ 1.467 mmol/l).
15
Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high
(≥ 5.17 mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at
baseline (≥ 4.39 - < 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
16
Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T18:00:00Z · SHA-256 5eee4543487d58354518319e0b1b7414c5442797ce74794c52c9bfc9f51dcbf7 · Passage 955415f0b40ff72c77ce39f7bf18ed6f3b81828ef2761be1f5c97feda81d26f9 · Zeichen 15533–16748 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.